{
  "source": "PA-Notification-Verquvo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1362-4\nProgram Prior Authorization/Notification\nMedication Verquvo® (vericiguat)\nP&T Approval Date 7/2021, 9/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background\nVerquvo (vericiguat) is indicated to reduce the risk of cardiovascular death and heart failure (HF)\nhospitalization following a hospitalization for heart failure or the need for outpatient IV diuretics, in\nadults with symptomatic chronic HF and ejection fraction less than 45%. Verquvo has a boxed\nwarning for embryo-fetal toxicity and should not be used during pregnancy.\n2. Coverage Criteriaa\nA. Initial Authorization\n1. Verquvo will be approved based on all the following criteria:\na. Diagnosis of symptomatic heart failure\n-AND-\nb. Ejection fraction is less than 45 percent\n-AND-\nc. Heart failure is classified as one of the following:\n(1) New York Heart Association Class II\n(2) New York Heart Association Class III\n(3) New York Heart Association Class IV\n-AND-\nd. One of the following:\n(1) Hospitalization for heart failure within the past six months\n(2) Outpatient IV diuretics for heart failure within the past three months\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Verquvo will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Documentation of a positive clinical response to Verquvo therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Verqu",
    " previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Verquvo [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; July 2023.\nProgram Prior Authorization/Notification – Verquvo\nChange Control\nDate Change\n7/2021 New program\n9/2022 Annual review. Updated references, added reauthorization criteria,\nadded state mandate footnote.\n11/2023 Annual review. Updated references.\n11/2024 Annual review with no changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}